Outlook Therapeutics’ Bevacizumab Proves Non-inferior to Ranibizumab in 12-Week Trial
After failing to show non-inferiority to ranibizumab at 8 weeks late last year, ONS-5010’s new 12-week data strengthens the case…
After failing to show non-inferiority to ranibizumab at 8 weeks late last year, ONS-5010’s new 12-week data strengthens the case…
![[Internal] Sling Therapeutics Phase 2b3 Thyroid eye disease](https://piemagazine.org/wp-content/uploads/sites/4/2025/01/Internal-Sling-Therapeutics-Phase-2b3-Thyroid-eye-disease-579x326.png)
